OCUGEN, INC. Accumulated Other Comprehensive Income
OCUGEN, INC. (OCGN) had Accumulated Other Comprehensive Income of $213.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-06
- 2026-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax $213.00K.
- 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $164.00K.
- 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $61.00K.
- 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax $58.00K.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax |
|---|---|
| 2026-06-30 | $213.00K 10-Q · filed 2026-08-06 |
| 2026-03-31 | $164.00K 10-Q · filed 2026-05-08 |
| 2025-12-31 | $61.00K 10-Q · filed 2026-08-06 |
| 2025-09-30 | $58.00K 10-Q · filed 2025-11-05 |
| 2025-06-30 | $12.00K 10-Q · filed 2025-08-04 |
| 2025-03-31 | $40.00K 10-Q · filed 2025-05-09 |
| 2024-12-31 | $48.00K 10-K · filed 2026-03-04 |
| 2024-09-30 | $23.00K 10-Q · filed 2024-11-14 |
| 2024-06-30 | $28.00K 10-Q · filed 2024-08-08 |
| 2024-03-31 | $25.00K 10-Q · filed 2024-05-14 |
| 2023-12-31 | $20.00K 10-K · filed 2025-03-05 |
| 2023-09-30 | $27.00K 10-K · filed 2024-04-16 |
| 2023-06-30 | $22.00K 10-K · filed 2024-04-16 |
| 2023-03-31 | $25.00K 10-K · filed 2024-04-16 |
| 2022-12-31 | $26.00K 10-K · filed 2024-04-16 |
| 2022-09-30 | $30.00K 10-K · filed 2024-04-16 |
| 2022-06-30 | $10.00K 10-K · filed 2024-04-16 |
| 2022-03-31 | $0.00 10-K · filed 2024-04-16 |
| 2021-12-31 | $0.00 10-K · filed 2023-02-28 |
| 2018-12-31 | $451.00 10-K · filed 2020-03-27 |
| 2017-06-30 | -$2.00K 10-Q · filed 2017-08-10 |
| 2017-03-31 | -$6.00K 10-Q · filed 2017-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |